

Development of Lead Therapeutic Antibody-Drug Conjugate Targeting CDCP1 for Pancreatic Cancer Treatment

Novelty Nobility Inc.
NOVELTY  NOBILITY

ONCOLOGY	Lead
Product Type	Antibody
Indication	PDAC(Pancreatic Ductal Adenocarcinoma)
Target	CDCP1
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Binds to CDCP1 overexpressed on pancreatic cancer cells • Inhibits pro-metastatic signaling pathways • Efficiently internalized into tumor cells and releases a potent topoisomerase II inhibitor via a cleavable linker • Induces DNA double-strand breaks, G2/M phase cell cycle arrest, and apoptosis • Elicits bystander effect through membrane-permeable payload diffusion
Competitiveness	<ul style="list-style-type: none"> • Exhibits strong <i>in vitro</i> and <i>in vivo</i> anti-tumor potency in CDCP1-expressing pancreatic cancer models • The topoisomerase II -targeting payload synergizes with CDCP1-driven RAS/EMT signaling, enabling the induction of selective cytotoxicity to aggressive tumor phenotypes • Overcomes resistance to conventional chemotherapies by targeting CDCP1-high, mesenchymal-like, and KRAS-mutant tumor cells • Achieves cancer cell-specific on-target delivery while minimizing binding to normal cells expressing basal levels of CDCP1
Development Stage	Lead
Route of Administration	Intravenous (<i>i.v.</i>)

Any unauthorized distribution or reproduction of this material is strictly prohibited.